• Eurofins Genomics joins flanders.bio

    Monday December 21st 2020

  • ONA Therapeutics, Absolute Antibody and RIC partner to create new type of biologic

    Friday December 18th 2020

  • Imec presents smallest finFET-based biosensor for high-sensitivity molecule detection

    Friday December 18th 2020

  • Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)

    Wednesday December 16th 2020

  • Mithra announces positive DSMB safety review and continuation of its Phase III Clinical Program Donesta® in menopause

    Wednesday December 16th 2020

  • OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform

    Tuesday December 8th 2020

  • Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Thursday December 3rd 2020

  • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

    Thursday December 3rd 2020

  • Your news here?

  • eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

    Wednesday December 2nd 2020

  • AbolerIS Pharma signed with Ouest Valorisation an exclusive world-wide license to develop new first-in-class anti-CD45RC monoclonal antibodies

    Wednesday December 2nd 2020

  • atbtherapeutics initiates agreement with iBio CDMO to manufacture game-changer atbodies to better treat cancer

    Tuesday December 1st 2020


Strategic Partners